Background. Poor nutritional status is associated with immunologic impairment and adverse health outcomes among adults infected with human immunodeficiency virus (HIV).
Since 2003, tremendous efforts have been underway to scale up care and treatment access for persons with human immunodeficiency virus (HIV) infection in resource-limited countries [1] . As a result, at least 3 million HIV-infected individuals in sub-Saharan Africa were receiving antiretroviral therapy (ART) by the end of 2008 [2] . The availability of ART in resourcelimited settings has dramatically decreased the morbidity and mortality among HIV-infected individuals worldwide. However, weight loss and malnutrition continue to be common problems among HIV-infected patients in such settings, even in the era of ART [3] [4] [5] . Previous studies have shown that low body mass index (BMI) at ART initiation was an independent predictor of mortality [6] [7] [8] [9] [10] .
The high rates of early mortality (death within 3 months) after ART initiation in resource-limited settings have been well documented [11] . However, few studies have examined the association between nutritional status at ART initiation and early mortality [4, 12] , and even these studies were limited by the use of broad BMI categories. In addition, data on the association between weight change in the first few weeks after ART initiation and the risk of subsequent death are still very limited, especially from resource-limited settings [13, 14] . An improved understanding of the role of nutritional status in HIV disease progression may help in the development of strategies to reduce mortality after ART initiation. To our knowledge, no previous study has related changes in middle upper arm circumference (MUAC) and hemoglobin (Hgb) concentrations to the risk of mortality after ART initiation.
Using data from HIV-infected patients from Dar es Salaam, Tanzania, in whom ART was initiated, we examined the associations between nutritional status, represented by BMI, MUAC, and Hgb concentrations at ART initiation, and death in the first 3 months of ART. Furthermore, we examined changes in weight, MUAC, and Hgb concentrations by 3 months after ART initiation in relation to the risk of death 3-6 months, 6-12 months, and .12 months after ART initiation.
METHODS

Study Population
Since November 2004, the Management and Development for Health program has provided the President's Emergency Plan for AIDS Relief-supported HIV care and treatment in Dar es Salaam, Tanzania. This has included laboratory and technical support and integrated prevention of mother-to-child transmission and tuberculosis (TB) services. Clinical care of all HIV-infected patients followed National AIDS Control Program and World Health Organization (WHO) guidelines [15, 16] . Antiretroviral drugs were provided free of charge by the Tanzanian government if the patient was eligible for ART initiation. Standard first-line ART regimens included 2 nucleoside reverse-transcriptase inhibitors, stavudine (d4T) or zidovudine (AZT) and lamivudine (3TC), plus 1 nonnucleoside reverse-transcriptase inhibitor, efavirenz (EFV) or nevirapine (NVP). To avoid drug interactions, EFV was substituted for NVP in patients receiving rifampin therapy for the treatment of TB. The patients considered in this analysis were adults (R15 years old) who were initiated ART between November 2004 and June 2009 and were ART-naive at ART initiation (n 5 20,573). We excluded pregnant women (n 5 1240) and patients without data on BMI (n 5 844) or MUAC (n 5 218) at ART initiation. After these exclusions, a total of 18,271 patients were available for analysis. The study was approved by institutional review boards for human research at the Harvard School of Public Health and at Muhimbili University of Health and Allied Sciences in Dar es Salaam, Tanzania.
Data Collection
After enrollment and ART initiation, patients were evaluated monthly. At each visit, they were examined by a physician and received adherence and nutrition counseling if necessary. A trained nurse measured the patient's height, weight, and MUAC by using calibrated instruments and standardized techniques [17] . BMI was calculated as the patient's weight in kilograms divided by the square of the patient's height in meters.
Physicians and nurses completed standard forms capturing demographic, clinical, and therapeutic information at baseline and follow-up visits. Data collected for the current study included age, sex, visit date, WHO HIV disease stage, TB history, current TB treatment, and ART regimen. Data reviewers were stationed at each clinic to ensure adequacy and completeness of the data recorded by the healthcare workers. Weekly quality assurance checks of the database were performed by the data management team to ensure data accuracy. A comprehensive patient tracking system was implemented to ensure that all patients who missed a visit or had an abnormal laboratory result were contacted by phone or in person to encourage them to return to the clinic.
Laboratory tests, including Hgb levels and CD4 1 cell counts, were performed at ART initiation and then monitored every 4 months. Patients taking AZT also had their Hgb levels measured 2 weeks after ART initiation to monitor for toxicity. Chest radiography and sputum analysis for TB screening were performed at ART initiation for all patients and for those with symptoms suggestive of TB during follow-up.
Statistical Analysis
Cox proportional hazard models were used to examine the associations between BMI, MUAC, and Hgb level at ART initiation and early mortality (defined as death within 3 months after ART initiation) and the associations between changes in weight, MUAC, and Hgb levels in the first 3 months of ART and subsequent mortality. We examined the possibility that the relationships between the risk of death and changes in weight, MUAC, and Hgb were nonlinear, using restricted cubic spline models [18, 19] . We grouped baseline BMI into the following categories: severe malnutrition (BMI, [20] . We grouped baseline MUAC as ,20.0 cm, 20.0 to ,22.0 cm, 22.0 to ,25.0 cm, 25.0 to ,27.0 cm, and R27.0 cm. Weight and MUAC changes in the first 3 months from ART initiation were categorized as decreases of R5% relative to the baseline value, decreases of ,5%, increases of %5%, or increases of .5%. Changes in Hgb concentrations were categorized as decreases of R10% relative to the baseline value, decreases of ,10%, increases of %10%, or increases of .10%. P values for trend were calculated by treating the median value of each category as a continuous variable in the proportional hazards models.
The following potential cofounders were included as covariates in the regression models: baseline age (,30, 30 ) at ART initiation was not associated with either a reduced or an increased risk of early mortality.
Patients with a baseline MUAC of ,20.0 cm had a 4.2-fold higher risk of early mortality compared with those with a baseline MUAC of R27 cm (95% CI, 3.3-5.2). The association between baseline MUAC and early mortality was attenuated, but remained statistically significant after further adjusting for baseline BMI (relative risk, 3.5; 95% CI, 2.6-4.7; MUAC ,20 vs R27 cm). Patients with an Hgb level of ,7.0 g/dL had a 3.5-fold independent increased risk compared with those with an Hgb level of R11.0 g/dL (relative risk, 3.5; 95% CI, 2.9-4.2).
All P values for trend were ,.001.
Nutritional Status Change After 3 Months of ART and Subsequent Risk of Mortality
After 3 months of ART, the median increases in weight, MUAC, and Hgb level from the time of ART initiation, were 2.6 kg (IQR, .4-5.2), .7 cm (IQR, 2.2 to 2.0), and 0.6 g/dL (IQR, 2.4 to 1.9), respectively. The correlation coefficient for the correlation between weight change and MUAC change was 0.50, compared with 0.82 for the correlation between baseline weight and baseline MUAC. In multivariate analyses after adjustment for age, sex, baseline BMI, CD4
1 cell counts, WHO HIV disease stage, oral candidiasis, diarrhea, TB treatment, TB history, ART regimen, and other potential confounders, increased mortality was noted with weight loss, MUAC decreases, and Hgb decreases after 3 months of ART. The P values for nonlinearity indicated statistically significant differences (P , .05), meaning that the relationships between changes in weight, MUAC, Hgb, and mortality were nonlinear ( Figure 1 ). Patients who lost R5% of their weight had a 5-fold increased risk of mortality compared with patients with weight gains of .5% (95% CI, 4.0-7.3). Patients whose MUAC decreased by R5% had a 5-fold risk of mortality compared with a Three person-months were assigned to each patient unless the patient died within 3 months after ART initiation, in which case the duration of follow-up was calculated from the ART initiation date to the death date. Patients whose Hgb concentrations decreased by R10% experienced a 2-fold higher risk of mortality than those whose Hgb concentrations increased .10% (95% CI, 1.4-3.0) ( Table 3) .
We further examined the associations between weight, MUAC, and Hgb changes in the first 3 months after ART initiation, in relation to the risk of death occurring after 3-6 months, 6-12 months, and .12 months of ART. Patients with weight loss of R5% at 3 months had a 14-fold higher risk of death after 3-6 months, compared with those with weight gains of .5% (95% CI, 8.8-21.1). Patients whose MUAC decreased by R5% had a 12-fold increased risk of death during the next 3 months (95% CI, 7.3-20.6). Weight loss and a decrease in MUAC in the first 3 months after ART initiation were also associated with a higher risk of mortality after 6 months of ART. However, the magnitude of the associations was much lower. An Hgb decrease after 3 months of ART was associated with a 3-fold higher risk of death during the next 3 months (95% CI, 1.6-5.0) but was not associated with deaths occurring after .6 months of ART (table 4) .
Association of Weight Change With Risk of Mortality Stratified by BMI at Time of ART Initiation
In this study, the association between weight change and mortality varied by baseline BMI (test for interaction, P 5 .09). Weight loss was positively associated with the risk of death across all baseline BMI strata, except in patients who were overweight (BMI, R25.0 kg/m 
DISCUSSION
In this large cohort of HIV-infected adults in Dar es Salaam, Tanzania, we found that lower BMI, MUAC, and Hgb concentrations at ART initiation were strongly associated with a greater risk of death within 3 months. Among patients who survived .3 months after ART initiation, those with weight loss, MUAC, or Hgb decreases in the first 3 months of ART were at a higher subsequent risk of death.
In the few studies that have documented weight change among HIV-infected patients receiving ART, patients, on average, tended to gain weight after ART initiation, especially those who were underweight at baseline [14, 21] . In this study, we found that the median increase in weight was 2.6 kg (IQR, .4-5.2) after 3 months of ART, slightly higher than that reported from the United States (1.9-kg median increase in weight after 16 weeks of ART [21] ). This difference could be due to the higher proportion of patients who were underweight and at an advanced stage of disease at ART initiation in our cohort, as well as to the more rapid gains associated with lower BMI levels. We also noted that the overall median increase in MUAC was .7 cm (IQR, 2.2 to 2.0) after 3 months of ART. Although the majority of our patients experienced increases in weight and MUAC, 20% and 26% of patients, respectively, experienced weight loss or a decrease in MUAC after 3 months of ART. This finding is consistent with the results from other studies documenting that weight loss and wasting continue to be common problems among HIV-infected patients, even in the era of ART [3, 5, 22] . With respect to hematologic status, although the median change in Hgb levels after 3 months of ART was an increase of 0.6 g/dL, 33% of patients had a decrease in Hgb levels after 3 months, compared with baseline levels.
Baseline BMI has been reported to be a significant predictor of early mortality after ART initiation [4, 11, 12] . Our results are consistent with these findings. Furthermore, we found that baseline MUAC and Hgb concentrations were inversely associated with the risk of death in the first 3 months, even after adjustment for baseline BMI. To our knowledge, no study has examined the association between baseline MUAC and the risk of mortality among patients receiving ART. Further study is warranted to test whether MUAC and MUAC changes are more sensitive predictors of death than baseline BMI and weight changes among patients receiving ART. Other studies have demonstrated that patients often experience subcutaneous fat loss (lipoatrophy) and/or relative visceral fat accumulation (lipohypertrophy) after ART initiation [23] [24] [25] . Compared with BMI, MUAC is easier to measure, because only a tape measure is needed. Furthermore, MUAC is useful in evaluating the nutritional status of pregnant women and assessing the condition of extremely sick patients who are unable to stand up.
Data on the association between weight change after ART initiation and risk of mortality are limited, especially in resource-limited settings. The Tufts Nutrition for Healthy Living study in the United States found that weight loss of R10% relative to baseline or the previous visit was significantly associated with a 4-6-fold increase in mortality, compared with maintenance or weight gain [26, 27] . Another study using combined data from Cambodia and Kenya found that weight gain of %5% at 3 months after ART initiation was associated with a 6-fold increased risk of death among persons who were underweight (BMI, ,18.5kg/m 2 ) [14] . In a study from Zambia, patients with baseline BMIs of ,16.0 kg/m 2 and weight loss after 6 months of ART had an 8-fold increased risk of mortality [13] . Our results are consistent with those from these previous studies. Furthermore, even among patients with normal baseline BMI, we found that a 5.4-fold increased risk of death was associated with weight loss of .5%. Therefore, a weight loss of .5% has considerable prognostic value, not only for underweight patients but also for patients with normal weight at ART initiation. In addition, we noted a stronger association between the change in nutritional status in the first 3 months after ART initiation and death occurring after 3-6 months of ART, compared with death occurring thereafter. Weight loss in the first 3 months was not a significant predictor of death after 1 year of ART, and Hgb decrease in the first 3 months was associated only with death 3-6 months after ART initiation. Death occurring 1 cell count (,50, 50-99, 100-199, R200), WHO HIV disease stage (I/II, III, IV), oral candidiasis (yes or no), diarrhea (yes or no), TB treatment (yes or no), TB history (yes or no), ART regimen (d4T, 3TC and NVP; d4T, 3TC and EFV; AZT, 3TC and NVP; AZT, 3TC and EFV), and weight change (R5.0% loss, ,5% loss, %5% gain, or .10% gain).
after 1 year of ART may be more related to recent changes in weight, MUAC, and Hgb than to changes in the first 3 months of ART.
Our findings suggest that it may be helpful to provide nutritional interventions before, and in the early weeks after, ART initiation. Increased appetite, side effects, and toxicity associated with ART make it difficult for patients to adhere to their treatment without adequate food [28] . There is some evidence that nutritional supplements improve adherence to medication regimens and patient retention after ART initiation [29] . Data on the impact of macronutrient and micronutrient supplements on immune reconstitution, HIV disease progression, and mortality are few and not conclusive, especially among patients receiving ART [30] [31] [32] [33] . In resource-limited countries where malnutrition is still a serious problem, feasible and effective interventions to mitigate the adverse impact of undernutrition and malnutrition need to be developed and tested for their ability to improve patients' prognoses.
To ensure that treatment is achieving viral suppression and that decisions about regimen switches are made at the appropriate time, it is critical to monitor disease progression for HIVinfected patients receiving ART [34, 35] . Viral load testing is the reference standard for monitoring HIV-infected patients [36] . However, in resource-limited settings, access to viral load measurements is still limited [37, 38] . In areas where viral load testing is not available, weight and MUAC might be considered as potential tools to monitor patients with AIDS, especially to , oral candidiasis (yes or no), diarrhea (yes or no), TB treatment (yes or no), TB history (yes or no), ART regimen (d4T, 3TC, and NVP; d4T, 3TC, and EFV; AZT, 3TC, and NVP; AZT, 3TC, and EFV), and weight change (R5% loss, ,5% loss, %5% gain, .5% gain). identify patients at high risk for death after ART initiation. However, because we were not able to include viral load measurements in this study, we were unable to validate weight loss and MUAC decreases against virologic failure as prognostic indicators. Although weight and MUAC measures are easy, inexpensive, and applicable for use in large clinical populations, they might not be sensitive enough to reflect patients' responses to ART. Our results, therefore, should not be used as evidence to replace and/or limit viral load testing among patients receiving ART. Until it is clearly suggested otherwise, continuing efforts should be undertaken to make viral load testing widely available in resource-limited settings.
In summary, in this large cohort of HIV-infected adults, we found that poor nutritional status at ART initiation was independently associated with a high risk of mortality within the first 3 months. Weight loss and MUAC decreases in the first 3 months of ART were associated with a further increased risk of subsequent mortality. To strengthen the benefits of ART in developing countries, the evaluation of nutritional intervention is warranted to improve and maintain the nutritional and clinical status of patients. Priorities for future studies include identifying risk factors for weight loss after ART initiation and examining the effect of nutritional interventions on disease progression and mortality among patients receiving ART. 
